Wednesday November 25 2009 | Biotechnology feed | All feeds

Abbott

Abbot Diagnostics Division, Maidenhead Berkshire, United Kingdom.

Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial

BioPortfolio no longer holds the full text of this article, it is however likley to be available via the below links:

Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into ... Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti- Platelet Therapy (DAPT) Trial. Thursday, August 13, 2009 9:01 AM ...
http://www.istockanalyst.com/article/viewiStockNews/articlei...
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into ... Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti- Platelet Therapy (DAPT) Trial. More than 2000 XIENCE V Patients May Also Be ...
http://www.prnewswire.com/news-releases/abbott-expands-xienc...
Press Releases for ABT Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti- Platelet Therapy (DAPT) Trial · Impax Laboratories Receives Final FDA ...
http://www.istockanalyst.com/press/ABT...
Abbott Laboratories (ABT) - Stock Market Report Aug 18, 2009 07:52 AM | ABT, BG, C, CPO, MOD · Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
...
http://www.istockanalyst.com/symbol/ABT...

Browse other news from this organisation: Abbott

(If any, Generated Automatically)

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.